TY - JOUR
T1 - Positron Emission Tomography to Improve Assessment of Interstitial Lung Disease in Patients With Systemic Sclerosis Eligible for Autologous Stem Cell Transplantation
AU - Broens, Bo
AU - van der Laken, Conny J
AU - Zwezerijnen, Gerben J C
AU - Nossent, Esther J
AU - Meijboom, Lilian J
AU - Spierings, Julia
AU - de Vries-Bouwstra, Jeska K
AU - van Laar, Jacob M
AU - Voskuyl, Alexandre E
N1 - Funding Information:
Boehringer Ingelheim and the Dutch Arthritis Society (under grant number 21-1-201) (partially) funded the F-FDG PET-CT study within the UPSIDE study. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. 18
Publisher Copyright:
Copyright © 2022 Broens, van der Laken, Zwezerijnen, Nossent, Meijboom, Spierings, de Vries-Bouwstra, van Laar and Voskuyl.
PY - 2022/7/5
Y1 - 2022/7/5
N2 - Positron emission tomography (PET) is a promising technique to improve the assessment of systemic sclerosis associated interstitial lung disease (SSc-ILD). This technique could be of particular value in patients with severe diffuse cutaneous SSc (dcSSc) that are possibly eligible for autologous hematopoietic stem cell transplantation (aHSCT). aHSCT is a potentially effective therapy for patients with severe dcSSc and ILD, leading to stabilization or improvement of lung function. However, there is a high need to improve patient selection, which includes (1) the selection of patients with rapidly progressive ILD for early rather than last-resort aHSCT (2) the prediction of treatment response on ILD and (3) the understanding of the mechanism(s) of action of aHSCT in the lungs. As previous studies with
18F-FDG PET in SSc-ILD and other forms of ILD have demonstrated its potential value in predicting disease progression and reactivity to anti-inflammatory treatment, we discuss the potential benefit of using this technique in patients with early severe dcSSc and ILD in the context of aHSCT. In addition, we discuss the potential value of other PET tracers in the assessment of ILD and understanding the mechanisms of action of aHSCT in the lung. Finally, we provide several suggestions for future research.
AB - Positron emission tomography (PET) is a promising technique to improve the assessment of systemic sclerosis associated interstitial lung disease (SSc-ILD). This technique could be of particular value in patients with severe diffuse cutaneous SSc (dcSSc) that are possibly eligible for autologous hematopoietic stem cell transplantation (aHSCT). aHSCT is a potentially effective therapy for patients with severe dcSSc and ILD, leading to stabilization or improvement of lung function. However, there is a high need to improve patient selection, which includes (1) the selection of patients with rapidly progressive ILD for early rather than last-resort aHSCT (2) the prediction of treatment response on ILD and (3) the understanding of the mechanism(s) of action of aHSCT in the lungs. As previous studies with
18F-FDG PET in SSc-ILD and other forms of ILD have demonstrated its potential value in predicting disease progression and reactivity to anti-inflammatory treatment, we discuss the potential benefit of using this technique in patients with early severe dcSSc and ILD in the context of aHSCT. In addition, we discuss the potential value of other PET tracers in the assessment of ILD and understanding the mechanisms of action of aHSCT in the lung. Finally, we provide several suggestions for future research.
KW - Hematopoietic Stem Cell Transplantation
KW - Humans
KW - Lung Diseases, Interstitial/complications
KW - Positron-Emission Tomography
KW - Scleroderma, Systemic/complications
KW - Transplantation, Autologous
KW - systemic sclerosis
KW - interstitial lung disease
KW - scleroderma
KW - stem cell transplantation
KW - positron emission tomography
KW - lung fibrosis
UR - http://www.scopus.com/inward/record.url?scp=85134199784&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2022.923869
DO - 10.3389/fimmu.2022.923869
M3 - Article
C2 - 35865521
SN - 1664-3224
VL - 13
JO - Frontiers in Immunology
JF - Frontiers in Immunology
M1 - 923869
ER -